Latigo Biotherapeutics Inc.
NASDAQ:LTGOMedical - Pharmaceuticals
+$0.76 today
- Market cap
- $800.64M
- Beta
- 0.00
Volume 0.21M
Average 0.38M
LTGO Cost of Revenue
Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.
Cost of Revenue history
Currency unavailable · from the income statement
No Cost of Revenue data reported for this period type.
Cost of Revenue vs competitors
How LTGO compares with its peers on the latest reported figures
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $313.15M USD | +11.4% | +7.6% | 39.3% | |
| LTM Mar 2026 | $151.86M USD | -3.5% | -9.1% | 20.7% | |
| LTM Mar 2026 | $15.25M USD | +7.1% | +12.1% | 45.0% | |
LTGOLatigo Biotherapeutics Inc. | — | — | — | — | — |
| Peer median (excluding LTGO) | — | +7.1% | +7.6% | 39.3% | |
Competitors are the stored peer set for LTGO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Latigo Biotherapeutics Inc.
NASDAQ:LTGO
Intrinsic Alpha fair value
Locked
Current Price
$13.31
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.